GlassScriptPhysician profile
Nicholas Rohs
NPI 1215226824
$147,246.44
in general payments reported to CMS, 2019-2025
21 companies · $16K in 2025
The $16K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $27K · 2021: $15K · 2022: $22K · 2023: $20K · 2024: $15K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Food and Beverage: $2,129 · Travel and Lodging: $109 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,405.50 |
| Food and Beverage | $2,129.00 |
| Travel and Lodging | $108.84 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $81,024.33 | 2019-2025 | Tagrisso, Imfinzi |
| Genentech USA, INC. | $25,368.84 | 2019-2024 | Tecentriq, Alecensa |
| Regeneron Pharmaceuticals, INC. | $8,057.47 | 2023-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $6,716.79 | 2021-2024 | |
| Emd Serono, INC. | $4,186.59 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,818.80 | 2025 | |
| Roche Diagnostics Corporation | $3,474.00 | 2025 | |
| Astrazeneca Uk Limited | $3,052.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,825.00 | 2023 | Exkivity |
| Regeneron Healthcare Solutions, INC. | $2,482.12 | 2022 | |
| Blueprint Medicines Corporation | $1,732.50 | 2020 | |
| Beigene, LTD. | $1,650.00 | 2021 | |
| Daiichi Sankyo INC. | $1,484.72 | 2024 | Enhertu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.41 | 2019-2021 | |
| Janssen Biotech, INC. | $232.34 | 2020-2025 | Rybrevant |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $150.00 | 2022 | |
| Amgen INC. | $146.89 | 2020-2022 | |
| Ambu INC. | $125.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $50.77 | 2022 | |
| Janssen Scientific Affairs, LLC | $20.04 | 2019 | |
| Rigel Pharmaceuticals, INC. | $16.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Rohs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.